Cong-Fei Xu, Assistant Professor
School of Biomedical Sciences and Engineering,
South China University of Technology
E-mail：xucf@scut.edu.cn
Education and Work Experience
2008-2012: University of Science and Technology of China, Bachelor, Biotechnology
2012-2017: University of Science and Technology of China, Doctor, Cell Biology
2017-2019: School of Medicine, South China University of Technology, Postdoctor
2019-now: School of Biomedical Sciences and Engineering, South China University of Technology, Assistant Professor
Scientific Achievements
C. F. Xu is mainly engaged in rational design of nanocarriers for delivering nucleic acid drugs including siRNA and CRISPR/Cas9 for of tumors and immune-related diseases treatment. He has published 14 articles in SCI journals as first authorship or corresponding authorship, including Nature Communications、Nano Letters、ACS Nano、Small、Biomaterials、Advanced Drug Delivery Reviews, etc., two of which were ESI highly cited articles.
Scientific Interests
RNAi, gene editing, drug delivery, tumor and immune-related diseases
Representative Publications
1. Cong-Fei Xu#, Guo-Jun Chen#, Ying-Li Luo, Yue Zhang, Gui Zhao, Zi-Dong Lu, Anna Czarna, Zhen Gu*, Jun Wang*, Rational Designs of In Vivo CRISPR-Cas Delivery Systems. Advanced Drug Delivery Reviews, 2019, doi.org/10.1016/j.addr.2019.11.005. (#Co-first author)
2. Yue Zhang#, Song Shen#, Gui Zhao, Cong-Fei Xu*, Hou-Bing Zhang, Ying-Li Luo, Zhi-Ting Cao, Jia Shi, Zhi-Bin Zhao, Zhe-Xiong Lian, Jun Wang*, In Situ Repurposing of Dendritic Cells with CRISPR/Cas9-Based Nanomedicine to Induce Transplant Tolerance. Biomaterials, 2019, 217, 119302. (*Co-corresponding author)
3. Cong-Fei Xu#, Dong-Dong Li#, Zhi-Ting Cao, Meng-Hua Xiong, Xian-Zhu Yang*, Jun Wang*, Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery. Nano Letters, 2019, 19, 2688−2693. (#Co-first author)
4. Cong-Fei Xu, Shoaib Iqbal, Song Shen, Ying-Li Luo, Xian-Zhu Yang*, Jun Wang*, Development of “CLAN” Nanomedicine for Nucleic Acid Therapeutics. Small, 2019, 15, e1900055.
5. Cong-Fei Xu#, Zi-Dong Lu#, Ying-Li Luo, Yang Liu, Zhi-Ting Cao, Song Shen, Hong-Jun Li, Jing Liu, Kai-Ge Chen, Zhi-Yao Chen, Xian-Zhu Yang, Zhen Gu, Jun Wang*, Targeting of NLRP3 Inflammasome with Gene Editing for the Amelioration of Inflammatory Diseases. Nature Communications, 2018, 9, 4092. (#Co-first author)
6. Ying-Li Luo#, Cong-Fei Xu#, Hong-Jun Li, Zhi-Ting Cao, Jing Liu, Ji-Long Wang, Xiao-Jiao Du, Xian-Zhu Yang*, Zhen Gu, Jun Wang*, Macrophage-Specific In Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. ACS Nano, 2018, 12, 994-1005. (#Co-first author, ESI Highly Cited Article)
7. Yang Liu#, Zhi-Ting Cao#, Cong-Fei Xu*, Zi-Dong Lu, Ying-Li Luo, Jun Wang*, Optimization of Lipid-Assisted Nanoparticle for Disturbing Neutrophils-Related Inflammation. Biomaterials, 2018, 172, 92-104. (*Co-corresponding author)
8. Cong-Fei Xu#, Hou-Bing Zhang#, Chun-Yang Sun, Yang Liu, Song Shen, Xian-Zhu Yang*, Yan-Hua Zhu, Jun Wang*, Tumor Acidity-Sensitive Linkage-Bridged Block Copolymer for Therapeutic siRNA Delivery. Biomaterials, 2016, 88, 48-59. (#Co-first author)
9. Cong-Fei Xu, Yang Liu, Song Shen, Yan-Hua Zhu, Jun Wang*, Targeting Glucose Uptake with siRNA-Based Nanomedicine for Cancer Therapy. Biomaterials, 2015, 51, 1-11.
10. Cong-Fei Xu, Jun Wang*, Delivery Systems for siRNA Drug Development in Cancer Therapy. Asian Journal of Pharmaceutical Sciences, 2015, 10, 1-12. (ESI Highly Cited Article)